DX
DXRX.LSE Diaceutics PLC
- Market cap
- GBX 172M
- P/E
- -
- P/B
- 4.44x
- ROE
- -28.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is DXRX.LSE undervalued?
Graham numberThe Graham number of Diaceutics PLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Diaceutics PLC fundamental analysis
No fundamental analysis for Diaceutics PLC yet.
Diaceutics PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Diaceutics PLC
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, that enables potential therapy eligibility for patients within hours of a diagnostic ev…
Full company profileDiaceutics PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Diaceutics PLC annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.59M | 7.37M | 10.4M | 13.4M | 12.7M | 13.9M | 19.5M | 23.7M | 32.2M | 38.4M | 69.8M |
| Gross Profit | 2.66M | 4.89M | 6.80M | 10.3M | 9.33M | 10.6M | 14.0M | 19.7M | 28.3M | 26.1M | 47.0M |
| Operating Income | 882K | 901K | 1.21M | 2.12M | -610K | 550K | 575K | -3.02M | -2.46M | 266K | -16.3M |
| EBITDA | 738K | 922K | 1.30M | 848K | 178K | 2.35M | 3.61M | 2.36M | 2.77M | 6.08M | -2.89M |
| Net Income | 747K | 663K | 632K | 398K | 263K | 561K | 724K | -1.75M | -1.70M | 97.0K | -11.1M |
| EPS | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | -0.02 | -0.02 | 0.00 | -0.13 |
| Balance Sheet | |||||||||||
| Total Assets | 3.44M | 5.49M | 7.81M | 22.4M | 43.5M | 45.0M | 48.3M | 46.3M | 48.6M | 50.0M | 52.2M |
| Total Liabilities | 2.43M | 3.61M | 5.18M | 2.24M | 3.28M | 4.36M | 5.74M | 5.56M | 8.76M | 9.53M | 13.4M |
| Shareholders' Equity | 1.01M | 1.88M | 2.63M | 20.1M | 40.2M | 40.6M | 42.5M | 40.8M | 39.9M | 40.5M | 38.8M |
| Cash & Short-term Investments | 1.29M | 3.07M | 2.07M | 11.7M | 25.3M | 19.7M | 19.8M | 16.7M | 12.7M | 7.34M | 8.10M |
| Total Debt | 1.44M | 2.09M | 3.75M | 108K | 118K | 1.56M | 1.33M | 1.21M | 1.06M | 1.15M | 2.09M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 674K | 1.53M | -954K | -627K | 253K | 570K | 5.10M | 1.31M | 651K | 1.50M | 13.7M |
| Capital Expenditure | 29.0K | 283K | 1.11M | 2.93M | 6.29M | 5.60M | 4.87M | 4.86M | 4.63M | 71.0K | 84.0K |
| Free Cash Flow | 645K | 1.25M | -2.06M | -3.55M | -6.04M | -5.03M | 278K | -3.54M | -3.98M | 1.43M | 13.6M |
| Ratios | |||||||||||
| ROE | 73.8% | 35.3% | 24.0% | 2.0% | 0.7% | 1.4% | 1.7% | -4.3% | -4.3% | 0.2% | -28.6% |
| ROA | 21.7% | 12.1% | 8.1% | 1.8% | 0.6% | 1.2% | 1.5% | -3.8% | -3.5% | 0.2% | -21.2% |
| Net Profit Margin | 16.3% | 9.0% | 6.1% | 3.0% | 2.1% | 4.0% | 3.7% | -7.4% | -5.3% | 0.3% | -15.9% |
| Debt to Equity | 1.43x | 1.11x | 1.43x | 0.01x | 0.00x | 0.04x | 0.03x | 0.03x | 0.03x | 0.03x | 0.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Diaceutics PLC dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | GBP 191K | 0.00 | 26.4% |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | GBX 300K | 0.00 | 47.5% |
| 2017 | GBX 300K | 0.00 | 45.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Diaceutics PLC
- Insiders 27.79%
- Institutions 68.55%
- Public & others 3.66%
- Shares outstanding 85.0M
- Free float 47.8M
Diaceutics PLC company profile
- Company name
- Diaceutics PLC
- Ticker
- DXRX.LSE
- ISIN
- GB00BJQTGV64
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 205
- Fiscal year end
- December
- Address
- Building Two, Belfast, United Kingdom, BT9 6GW
- Website
- diaceutics.com
About Diaceutics PLC
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, that enables potential therapy eligibility for patients within hours of a diagnostic event, enabling teams to act while treatment decisions are still pending; DXRX Physician Mapping that examines physician testing behavior using patient level data to determine testing rates, methodology, and physician to lab relationship; DXRX Lab Mapping that offers insights into labs currently testing patients diagnosed with a specific disease or biomarker; and DXRX Disease Testing Rate Tracker, which delivers biomarker testing rate reports. In addition, the company offers scientific and advisory services. It operates in North America, the United Kingdom, Europe, Asia, and internationally. The company was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.
Diaceutics PLC management
10- Mr. Peter KeelingFounder & Non-Executive Chairman · born 1960
- Mr. Ryan KeelingCEO & Director · born 1982
- Mr. Nicholas Stewart RobertsCFO, Secretary & Director · born 1982
- Mr. Jordan Russell ClarkChief Data Officer? & Executive Director · born 1984
- Kerri DonaldsonVice President of Operations
- Ken RuppelVice President of Scientific & Medical Services
- Ms. Lauren DeWitt ShellyExecutive VP, General Counsel, Group Company Secretary & Director
- Marianna SciortinoVice President of Sales
- Ms. Sandra BlakeChief Marketing & People Officer
- Ms. Susanne MunkstedChief Growth Officer